Camptothecin

Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform

Retrieved on: 
Monday, April 8, 2024
Gene silencing, Irinotecan, Colorectal cancer, Immunotherapy, Triple-negative breast cancer, Mouse, Observation, Endocytosis, Cancer, Christian democracy, SN-38, Senior, Camptothecin, Conjugation, AACR, TSX, Treatment, Neoplasm, CRC, Poster, HT-29, TNBC, PDC, Vaccine

MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that highlight the versatility and flexibility of the Company’s SORT1+ Technology™ platform.

Key Points: 
  • MONTREAL, April 08, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that highlight the versatility and flexibility of the Company’s SORT1+ Technology™ platform.
  • The study also demonstrated synergistic anti-tumor efficacy and good tolerability with the combination of two peptide drug conjugates with different payloads.
  • “In addition to our lead peptide-drug conjugate, sudocetaxel zendusortide, these latest data highlight the promising tolerability and anti-tumor effects of our investigational camptothecin-peptide conjugates, further demonstrating the versatility and flexibility of the platform.
  • In the poster presented at AACR, the investigators noted that SORT1 gene silencing inhibits camptothecin-conjugate uptake in human HT-29 colorectal adenocarcinoma cells.

Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 

Retrieved on: 
Monday, April 8, 2024
Sarah Cannon Research Institute, B-cell leukemia, AML, B-ALL, Patient, Webcast, Neoplasm, Acute myeloid leukemia, Cancer, Syndrome, Spacecraft, Camptothecin, AACR, DLT, PALO, Antibody, Drug development, Safety, Infrared spectroscopy correlation table, MDS, Therapy, ADC, Drug resistance, Pharmaceutical industry

PALO ALTO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today presented positive preliminary Phase 1 data for VIP236 and updates on pipeline progress at the American Association for Cancer Research (AACR) Annual Meeting 2024.

Key Points: 
  • We are still in dose escalation and are starting to see tumor reduction after only two doses.
  • The study's main objective is to determine a safe dose and schedule for VIP236 for further clinical development.
  • As the study progresses through the dose escalation, Vincerx will present additional Phase 1 data for VIP943 on or around the 2024 European Hematology Association Annual Meeting in June 2024.
  • An archived replay of the webcast will be available on the Vincerx Investor Page website following the conclusion of the live event.

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors

Retrieved on: 
Monday, April 8, 2024
Colorectal cancer, Patient, SAN, Cancer, Epithelial cell adhesion molecule, Camptothecin, Therapy, Safety, ADC

SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the first patient has been dosed in a Phase 1 dose escalation study ( NCT06265688 ) of CX-2051 in patients with advanced solid tumors.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the first patient has been dosed in a Phase 1 dose escalation study ( NCT06265688 ) of CX-2051 in patients with advanced solid tumors.
  • CX-2051 is a masked PROBODY® antibody drug conjugate (ADC) directed toward epithelial cell adhesion molecule (EpCAM), a cell-surface target that is highly expressed across many cancer types including colorectal, gastric, endometrial, and ovarian cancers.
  • “EpCAM is a high potential ADC target present at high levels on many solid cancers.
  • CX-2051 has been optimized using our tailored masking strategies and possesses a potent cytotoxic payload ideally suited to specific EpCAM positive tumor types, including colorectal cancer.

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 11, 2024
Therapy, EDT, Head, CD3, SAN, Investigational New Drug, Cancer, EGFR, Research, Biotechnology, Partnering, TCE, Epithelial cell adhesion molecule, Investment, Melanoma, FDA, Amgen, Therapeutic index, Food, Camptothecin, Gastrointestinal tract, Bladder cancer, Drug discovery, CRC, ADC, Bristol Myers Squibb, BMS, Safety, Kidney, Cytokine, Webcast, Tumor microenvironment, PDT, Patient, Workforce, IND, Trial of the century, Colorectal cancer, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported full year 2023 financial results and provided a business update.

Key Points: 
  • Throughout 2023, CytomX made substantial progress across all research partnerships including the commencement of programs under its new alliances with Regeneron and Moderna.
  • In 2023, CytomX remained focused on controlling costs and efficiently allocating capital towards its lead pipeline programs.
  • General and administrative expenses in the fourth quarter of 2023 were $7.8 million compared to $10.1 million in the corresponding period in 2022.
  • CytomX management will host a conference call and simultaneous webcast today at 5 p.m. EDT (2 p.m. PDT) to discuss the financial results and provide a business update.

Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 6, 2024
Senior, Research, Fulvestrant, Sale, University, NBI, Tax, MSAT, Plasma, CD28, BTC, NASDAQ Biotechnology Index, Pain, Rat, BLA, Standard of care, Antibody, HER2, MD Anderson Cancer Center, Abstract (summary), GAAP, Therapy, Carcinoma, Abstract, Depreciation, Partnership, Camptothecin, Manuscript, Conference, Partner, IND, NMPA, Jazz Pharmaceuticals, PFS, BeiGene, FDA, Spacecraft, Pembrolizumab, CDX, ADC, OS, Society, Patient, Pharmaceutical industry

Financial Results for the Year Ended December 31, 2023

Key Points: 
  • Financial Results for the Year Ended December 31, 2023
    Revenue was $76.0 million in 2023 compared to $412.5 million in 2022.
  • Higher interest income in 2023 was due to income earned on higher cash resources and at higher rates of return in 2023.
  • “We are happy to report a continued reduction of our operating cash burn and operating losses during 2023 compared to 2022,” said Chris Astle, Ph.D., Senior Vice President and Chief Financial Officer of Zymeworks.
  • Reconciliations between historical GAAP and non-GAAP information are contained at the end of this press release following the accompanying financial data.

Lights, Cancer, Action! Sahmyook University Researchers Develop a Light-Responsive Novel Drug Delivery System Against Skin Cancer

Retrieved on: 
Thursday, January 25, 2024
DOX, Nanofiber, Research, Professor, Skin, Heat, Nanorod, DDS, Sahmyook University, Skin cancer, Northern Rail, Camptothecin, Gold, CPT, Journal, Psoriasis, Pharmacotherapy, Health, Motivation, NFS, Pharmaceutical industry

SEOUL, South Korea, Jan. 25, 2024 /PRNewswire/ -- Nanotechnology-based drug delivery systems (DDS) offer several advantages, such as enhanced bioavailability and controlled drug release with reduced dosage. Recently, Sahmyook University researchers have developed a light-responsive DDS to treat skin cancer. By incorporating gold nanorods into the matrix of nanofibers, the study demonstrates external control over the release of anticancer drugs in a sequential and controlled method. This innovative DDS holds promise for future real-life nanotech-based applications in healthcare.

Key Points: 
  • SEOUL, South Korea, Jan. 25, 2024 /PRNewswire/ -- Nanotechnology-based drug delivery systems (DDS) offer several advantages, such as enhanced bioavailability and controlled drug release with reduced dosage.
  • Recently, Sahmyook University researchers have developed a light-responsive DDS to treat skin cancer.
  • In this light, a team of researchers led by Professor Myoung-Hwan Park from Sahmyook University in South Korea has developed a light-responsive nanofiber-based novel drug delivery system (DDS) targeting skin cancer.
  • Accordingly, the integration of nanofibers with on-demand drug delivery systems can open up new possibilities for drug therapy."

CytomX Therapeutics Outlines 2024 Company Priorities and Milestones

Retrieved on: 
Thursday, January 4, 2024
Camptothecin, Therapeutic index, Immunotherapy, Lung cancer, Cytokine, Drug discovery, CRC, Tumor microenvironment, Amgen, Biotechnology, IND, Kidney, Bladder cancer, Research, Colorectal cancer, EGFR, MSS, Epithelial cell adhesion molecule, Melanoma, SAN, Therapy, Cancer, Head, Neoplasm, Gastrointestinal tract, Toxicity, Ipilimumab, Patient, Bristol Myers Squibb, Partnering, ADC, NSCLC, CD3, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced its 2024 company priorities and anticipated milestones for its wholly-owned and partnered pipeline.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced its 2024 company priorities and anticipated milestones for its wholly-owned and partnered pipeline.
  • “With INDs recently filed for wholly-owned programs, CX-2051 and CX-801, and continued progress in dose escalation with our Probody® T-Cell engager, CX-904, CytomX is well positioned as we enter 2024.
  • CytomX has a consistent track record of forming new strategic research and development alliances and achieving preclinical research and clinical milestones.
  • Cash runway is projected to the second half of 2025, excluding any potential milestones from existing collaborations or new business development.

WuXi XDC Enters into Partnership Agreement with IntoCell, Enabling Clients to Accelerate ADC Discovery and Development

Retrieved on: 
Wednesday, January 3, 2024
PCC, MOU, Spacecraft, CMC, Camptothecin, Partnership, Development, ADC, Wuxi, Fine chemical

Under the agreement, IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate (OHPASTM) Linker and novel Camptothecin drugs called NexatecansTM, a new class of OHPAS-able Camptothecins.

Key Points: 
  • Under the agreement, IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate (OHPASTM) Linker and novel Camptothecin drugs called NexatecansTM, a new class of OHPAS-able Camptothecins.
  • WuXi XDC will provide fully integrated, one-stop bioconjugate platform and end-to-end CRDMO services.
  • This synergy will empower clients of both parties to accelerate PCC (Pre-clinical candidates) selection further, develop more next-generation ADCs and other bioconjugates, and expedite the CMC development process.
  • It demonstrates WuXi XDC's platform development strategy, namely to grow continually and evolve to help our clients to accelerate and transform the discovery, development and manufacturing of ADCs and other bioconjugates. "

Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 14, 2023
ASH, ADC, EMA, Patient, Camptothecin, Research, Therapy, Cancer, Oncogene, Poster, Multiple myeloma, Hematology, PALO, Safety, Therapeutic index, IND, DLBCL, Prednisone, Mantle cell lymphoma, Tumor microenvironment, SMDC, Society, RNA, Venetoclax, Corporation, Spacecraft, SME, Salivary gland tumour, MCL1, Cohort, European Medicines Agency, PDX, B-cell lymphoma, University, HER2, Acute lymphoblastic leukemia, Myelodysplastic syndrome, PTCL, MYC, MCL, Neoplasm, CPT, Peripheral T-cell lymphoma, Small and medium-sized enterprises, CDK9, FDA, RNA polymerase II, NIH, Toxicity, Vaccine, Pharmaceutical industry, Fine chemical, Medical imaging, Rare-earth element, Cryptocurrency

PALO ALTO, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • “We continue to take a very disciplined approach to our portfolio, focusing our resources on our two lead programs, VIP943 and VIP236.
  • We will present new data on robust preclinical activity at the 65th American Society for Hematology Meeting (ASH 2023) in December.
  • Collaborators from the University of Calgary will present a poster at ASH 2023 showing preclinical activity in pediatric leukemia.
  • For the quarter ended September 30, 2023, Vincerx reported a net loss of approximately $9.7 million, or $0.46 per share, compared to a net loss of approximately $16.9 million, or $0.80 per share, for the quarter ended September 30, 2022.

Peel Therapeutics to Present Data on its TOP1 Inhibitor PEEL-224 at the Connective Tissue Oncology Society Annual Meeting and Society for Immunotherapy of Cancer Annual Meeting

Retrieved on: 
Wednesday, November 1, 2023
Neoplasm, Society for Immunotherapy of Cancer, Traditional Chinese characters, Symantec Endpoint Protection, PD-1, Colorectal cancer, SALT, DNA, Memorial Sloan Kettering Cancer Center, Progress, Pharmacokinetics, SITC, Immunotherapy, Cancer, Clinical trial, Camptothecin, Annual general meeting, DNA repair, Safety, Society, Therapy, Patient, Toxicity, Happy Tree Friends, Sarcoma, Pharmaceutical industry, Camptotheca

PEEL-224 originates from Camptotheca acuminata, a toxin found in the Happy Tree from China.

Key Points: 
  • PEEL-224 originates from Camptotheca acuminata, a toxin found in the Happy Tree from China.
  • Camptothecin is a TOP1 inhibitor that interferes with DNA repair and kills damaged cells.
  • PEEL-224's modified TOP1 inhibitor payload and unique delivery system may offer clinical advantages to patients with solid tumors.
  • We are pleased by our continued progress and the efforts of our team to test if PEEL-224 will benefit patients in need."